310 related articles for article (PubMed ID: 18482691)
1. Pinning down the polo-box domain.
Lee KS; Idle JR
Chem Biol; 2008 May; 15(5):415-6. PubMed ID: 18482691
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
Chem Biol; 2008 May; 15(5):459-66. PubMed ID: 18482698
[TBL] [Abstract][Full Text] [Related]
3. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1.
Reindl W; Strebhardt K; Berg T
Anal Biochem; 2008 Dec; 383(2):205-9. PubMed ID: 18793607
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1.
Srinivasrao G; Park JE; Kim S; Ahn M; Cheong C; Nam KY; Gunasekaran P; Hwang E; Kim NH; Shin SY; Lee KS; Ryu E; Bang JK
PLoS One; 2014; 9(9):e107432. PubMed ID: 25211362
[TBL] [Abstract][Full Text] [Related]
5. Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides.
Zhao XZ; Hymel D; Burke TR
Bioorg Med Chem; 2017 Oct; 25(19):5041-5049. PubMed ID: 28285924
[TBL] [Abstract][Full Text] [Related]
6. Structure of the catalytic domain of human polo-like kinase 1.
Kothe M; Kohls D; Low S; Coli R; Cheng AC; Jacques SL; Johnson TL; Lewis C; Loh C; Nonomiya J; Sheils AL; Verdries KA; Wynn TA; Kuhn C; Ding YH
Biochemistry; 2007 May; 46(20):5960-71. PubMed ID: 17461553
[TBL] [Abstract][Full Text] [Related]
7. Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding.
Emmitte KA; Adjabeng GM; Andrews CW; Alberti JG; Bambal R; Chamberlain SD; Davis-Ward RG; Dickson HD; Hassler DF; Hornberger KR; Jackson JR; Kuntz KW; Lansing TJ; Mook RA; Nailor KE; Pobanz MA; Smith SC; Sung CM; Cheung M
Bioorg Med Chem Lett; 2009 Mar; 19(6):1694-7. PubMed ID: 19237286
[TBL] [Abstract][Full Text] [Related]
8. Selectivity-determining residues in Plk1.
Kothe M; Kohls D; Low S; Coli R; Rennie GR; Feru F; Kuhn C; Ding YH
Chem Biol Drug Des; 2007 Dec; 70(6):540-6. PubMed ID: 18005335
[TBL] [Abstract][Full Text] [Related]
9. Structures of the wild-type and activated catalytic domains of Brachydanio rerio Polo-like kinase 1 (Plk1): changes in the active-site conformation and interactions with ligands.
Elling RA; Fucini RV; Romanowski MJ
Acta Crystallogr D Biol Crystallogr; 2008 Sep; 64(Pt 9):909-18. PubMed ID: 18703838
[TBL] [Abstract][Full Text] [Related]
10. Identification of acylthiourea derivatives as potent Plk1 PBD inhibitors.
Yun T; Qin T; Liu Y; Lai L
Eur J Med Chem; 2016 Nov; 124():229-236. PubMed ID: 27592392
[TBL] [Abstract][Full Text] [Related]
11. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
Shan HM; Shi Y; Quan J
ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850
[TBL] [Abstract][Full Text] [Related]
12. Molecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy.
Shakil S; Baig MH; Tabrez S; Rizvi SMD; Zaidi SK; Ashraf GM; Ansari SA; Khan AAP; Al-Qahtani MH; Abuzenadah AM; Chaudhary AG
Semin Cancer Biol; 2019 Jun; 56():47-55. PubMed ID: 29122685
[TBL] [Abstract][Full Text] [Related]
13. Dynamic and multi-pharmacophore modeling for designing polo-box domain inhibitors.
Sakkiah S; Senese S; Yang Q; Lee KW; Torres JZ
PLoS One; 2014; 9(7):e101405. PubMed ID: 25036740
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain.
Chen Y; Zhang J; Li D; Jiang J; Wang Y; Si S
Oncotarget; 2017 Jan; 8(1):1234-1246. PubMed ID: 27902479
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the Allosteric Communication between the Polo-Box Domain and the Catalytic Domain in Plk1 by Small Compounds.
Raab M; Sanhaji M; Pietsch L; Béquignon I; Herbrand AK; Süß E; Gande SL; Caspar B; Kudlinzki D; Saxena K; Sreeramulu S; Schwalbe H; Strebhardt K; Biondi RM
ACS Chem Biol; 2018 Aug; 13(8):1921-1931. PubMed ID: 29927572
[TBL] [Abstract][Full Text] [Related]
16. A fluorescence polarization assay for the discovery of inhibitors of the polo-box domain of polo-like kinase 1.
Reindl W; Strebhardt K; Berg T
Methods Mol Biol; 2012; 795():69-81. PubMed ID: 21960216
[TBL] [Abstract][Full Text] [Related]
17. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
Shin SB; Woo SU; Yim H
J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
[TBL] [Abstract][Full Text] [Related]
18. Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain.
Scharow A; Knappe D; Reindl W; Hoffmann R; Berg T
Chembiochem; 2016 Apr; 17(8):759-67. PubMed ID: 26634982
[TBL] [Abstract][Full Text] [Related]
19. Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.
Yuan J; Sanhaji M; Krämer A; Reindl W; Hofmann M; Kreis NN; Zimmer B; Berg T; Strebhardt K
Am J Pathol; 2011 Oct; 179(4):2091-9. PubMed ID: 21839059
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1.
Berg A; Berg T
Chembiochem; 2016 Apr; 17(8):650-6. PubMed ID: 26662918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
